Assessment of efficacy of trastuzumab (Herceptin) comprising adjuvant therapy of HER2+ breast cancer patients determined based upon statistical analysis of overall survival (OS) and disease-free survival (PFS)

Abstract

IntroductionIn patients suffering from breast cancer, adjuvant radiation, chemotherapy, or immunotherapy, which immediately follow the surgery as the first line therapy, greatly improve overall (OS) and disease-free survival (DFS). Various regimens of adjuvant therapy for these patients have been tested contingent upon the clinical staging. Inclusion of adjuvant immunotherapy is particularly promising. Specific aimThe aim of this study was to assess efficacy of trastuzumab(Herceptin) -comprising adjuvant immunotherapy in terms of overall and diseasefree survival as compared to other adjuvant therapies. Patients Results OS Conclusion These results demonstrate the great benefits of inclusion of immunotherapy as the adjuvant Original ResearchJagielska et al. Molecular and Cellular Therapies (2018) 6:2 c o m p o n e n t a s c u r r e n t l y t h e b e s t o v e r a l l therapeutic strategy for the patients suffering breast cancers. As this strategy greatly exceeds any other therapeutic options available for practicing oncologists at the present time, it definitely justifies allocation of all needed public resources, while assuring highest quality health service for the patients in Poland.